Asset Details
Do you wish to reserve the book?
Estimated impact of long‐acting injectable PrEP in South Africa: a model comparison analysis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Estimated impact of long‐acting injectable PrEP in South Africa: a model comparison analysis
Do you wish to request the book?
Estimated impact of long‐acting injectable PrEP in South Africa: a model comparison analysis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Estimated impact of long‐acting injectable PrEP in South Africa: a model comparison analysis
2025
Overview
Introduction
Long‐acting injectable cabotegravir (CAB‐LA) demonstrated superiority to daily tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for human immunodeficiency virus (HIV) pre‐exposure prophylaxis (PrEP) in two clinical trials. This analysis projects the impact of expanding PrEP coverage with CAB‐LA in South Africa between 2022 and 2042.
Methods
Three independently calibrated models of HIV transmission in South Africa (Synthesis, EMOD‐HIV, Thembisa) projected HIV acquisitions and effective coverage (average PrEP coverage across exposure groups, weighted by HIV incidence in the absence of PrEP in each group) over 20 years under multiple scenarios of PrEP expansion compared to no PrEP expansion. PrEP expansion scenarios differed in targeted overall coverage, speed of expansion, coverage of high‐exposure groups, and relative coverage of women and men.
Results
Achieving 5% PrEP coverage with CAB‐LA by 2032 prioritizing high‐exposure groups resulted in 49% (Synthesis), 18% (EMOD‐HIV), and 8% (Thembisa) effective coverage and averted a median of 43%, 29% and 10% of new HIV acquisitions, respectively. Similar expansion with TDF/FTC resulted in lower impact by 19 percentage points (pp), 18pp and 3pp, respectively. Increasing CAB‐LA coverage to 15% led to an additional 7pp, 12pp and 16pp, respectively, of HIV acquisitions averted. Achieving 5% CAB‐LA coverage expanding to women only resulted in a lower impact by 16pp (Synthesis) and 13pp (EMOD‐HIV), and a higher impact by 2pp (Thembisa). Scenarios with similar effective coverage resulted in comparable impact estimates across models.
Conclusions
Offering CAB‐LA in South Africa may substantially impact the HIV epidemic based on these projections. Effective coverage proved to be a good predictor of intervention effectiveness.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
Subject
/ Adult
/ Anti-HIV Agents - administration & dosage
/ CAB‐LA
/ Emtricitabine - administration & dosage
/ Female
/ HIV
/ HIV Infections - epidemiology
/ HIV Infections - prevention & control
/ HIV Infections - transmission
/ Human immunodeficiency virus
/ Humans
/ Male
/ Pre-Exposure Prophylaxis - methods
/ Pyridones - administration & dosage
/ Tenofovir - administration & dosage
/ Women
